Kura Oncology (KURA) to Release Earnings on Tuesday

Kura Oncology (NASDAQ:KURA) is expected to be announcing its earnings results before the market opens on Tuesday, February 25th. Analysts expect the company to announce earnings of ($0.65) per share and revenue of $57.96 million for the quarter.

Kura Oncology Price Performance

Shares of KURA stock opened at $8.28 on Tuesday. The company’s 50-day simple moving average is $8.44 and its two-hundred day simple moving average is $14.43. Kura Oncology has a one year low of $6.98 and a one year high of $24.17. The company has a market capitalization of $643.85 million, a P/E ratio of -3.51 and a beta of 0.78. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.47 and a quick ratio of 11.47.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on KURA shares. BTIG Research cut shares of Kura Oncology from a “buy” rating to a “neutral” rating in a research report on Thursday, February 6th. TD Cowen restated a “buy” rating on shares of Kura Oncology in a research report on Thursday, November 21st. Scotiabank dropped their target price on shares of Kura Oncology from $18.00 to $10.00 and set a “sector perform” rating on the stock in a research report on Wednesday, January 8th. Jefferies Financial Group decreased their price target on shares of Kura Oncology from $32.00 to $28.00 and set a “buy” rating on the stock in a research note on Thursday, November 21st. Finally, Bank of America decreased their target price on shares of Kura Oncology from $36.00 to $29.00 and set a “buy” rating on the stock in a report on Friday, November 22nd. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $27.13.

Insider Buying and Selling at Kura Oncology

In other news, insider Mollie Leoni sold 4,963 shares of the firm’s stock in a transaction on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $39,058.81. Following the completion of the sale, the insider now owns 88,253 shares in the company, valued at approximately $694,551.11. This trade represents a 5.32 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Thomas James Doyle sold 4,949 shares of the firm’s stock in a transaction on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total transaction of $38,948.63. Following the completion of the sale, the senior vice president now owns 88,193 shares of the company’s stock, valued at $694,078.91. This trade represents a 5.31 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 11,729 shares of company stock valued at $92,307. Insiders own 5.50% of the company’s stock.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.